Jose E. Garcia-Vargas

Alpha emitter radium-223 and survival in metastatic prostate cancer.

I Syndikus, J Kliment, S. Fosså, 2013, The New England journal of medicine.

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

N. James, A. Cross, Chris Parker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.